FundLens
59
Pharma & HealthcareHold

UTI Healthcare

UTI · Direct–Growth · rank #5 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
22.0%
+21.3% vs index
3 Years
23.1%
+11.5% vs index
5 Years
17.7%
+7.6% vs index
Since launch
16.5%

Year-by-year performance

last entry = YTD
2021
+20.4%
2022
-11.3%
2023
+39.6%
2024
+44.3%
2025
-2.2%
2026
+24.0%

Why this score

UTI Healthcare scores 59/100 — #5 of 19 Pharma & Healthcare fund (Hold). It stands out for 3y return and 5y return — beating 71% of peers on 3y return. The main drag is its expense ratio (better than only 19% of peers).

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

3Y return23.06% · 71st percentile in category
5Y return17.74% · 65th percentile in category
Expense ratio1.34% · 19th percentile in category
Sharpe ratio1.06 · 72nd percentile in category
Sortino ratio1.71 · 80th percentile in category
Volatility16.04 · 34th percentile in category

Top holdings

top 5 = 28.2% of portfolio
1.Sun Pharmaceutical Industries Ltd7.44%
2.Divi's Laboratories Ltd6.46%
3.Dr. Reddy's Laboratories Ltd5.78%
4.Ajanta Pharma Ltd4.29%
5.Max Healthcare Institute Ltd4.2%

46 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds